Working with our partners, BC Centre for Disease Control and KIT, FUSION GENOMICS has identified a need to develop surveillance tests that characterize two complex viral infections: Influenza and Hepatitis C.


We are also one of the founding members of the IDENTIFy Consortium, below:

The IDENTIFy Consortium

FUSION GENOMICS is one of the founding members of the IDENTIFy Consortium, an international organization developing a revolutionary diagnostic platform that will survey, monitor and predict the occurrence neglected infectious diseases (Zoonotic Diseases, Tuberculosis, Malaria, Helminthic infections, HIV, Ebola) to better understand their dynamics so the most appropriate preventive measures can be taken. IDENTIFy has brought together an expert, multidisciplinary, cross-continent collaborative team with expertise in genomic, biological and clinical expertise in infectious disease. IDENTIFy is connected with established laboratory and clinical facilities.

Infectious diseases constitute a major health and socio-economic burden in underprivileged societies in low and middle income countries. The use of a single standardized test differentiating a wide range of pathogens enables a more efficient use of the laboratory services while reducing the risk of misdiagnosis and the inappropriate use of antibiotics.


As part of the consortium, FUSION GENOMICS is using their QUANTUMProbes and Next Generation Sequencing to develop field-applicable, robust and cost-effective standardized assays with real-time processing to rapidly identify human disease genetic signatures.

Fusion’s revolutionary approach — optimizing the diagnosis of infectious diseases close to the interface of the clinician and patient — uses a single protocol to reduce the burden on local diagnostic infrastructures in resource-poor settings. The pipeline will be supported by an online bioinformatics tool for accurate data interpretation and direct clinical use, facilitating immediate patient management decisions and disease control in those areas where it is most needed.

Other IDENTIFy Members


  • KIT Biomedical Research, Royal Tropical Institute, Netherlands. Unique expertise in infectious disease research, antimicrobial resistance, diagnostic development and diagnostic services.
  • London School of Hygiene and Tropical Medicine, UK. Specialized in the genomic epidemiology of infectious diseases, including malaria and tuberculosis, bioinformatics and population genetics.


  • Ifakara Health Institute (IHI), Tanzania. An independent, non-profit that is very experienced with routine diagnosis of bacterial infections. IHI will perform diagnosis, patient management, and field evaluation of the development assays and any other test that will be required.

For more about FUSION GENOMICS, see News, Meet Our People, or Contact us. Investors interested in discussing backing for FUSION GENOMICS, please Contact us..